|
Patent landscape, scope, and claims summary: |
US Patent 5,955,422: Claims, Scope, and US Patent Landscape—Erythropoietin Purified From Mammalian Cell Culture and Human Serum Albumin Formulations
What does US 5,955,422 claim, and how broad is the claim scope?
US 5,955,422 has two independent claim-like structures (labeled 1 and 2 in the excerpt). Both center on (1) human erythropoietin (EPO) and (2) formulation conditions that anchor novelty to production source and a specific excipient.
Claim 1 (composition)
Claim 1 recites a pharmaceutical composition with a “therapeutically effective amount” of human erythropoietin plus a pharmaceutically acceptable diluent, adjuvant, or carrier, with the key limitation:
- “said erythropoietin is purified from mammalian cells grown in culture.”
Scope implications
- Product identity is defined by origin and purification route, not by amino-acid sequence, glycoform pattern, or specific purification steps.
- The claim is broad across mammalian cell culture systems (no limitation to a specific cell line, process parameters, or bioreactor scale).
- The claim does not expressly require:
- absence of impurities (other than what results from “purified”),
- a particular degree of purity,
- a specific glycosylation profile,
- a particular formulation class (it permits “diluent, adjuvant or carrier” broadly).
Critical pressure points
- “Purified from mammalian cells grown in culture” is a product-by-process limitation. That tends to create scope that is meaningful for infringement when the accused EPO is produced by a different source (for example, different host, non-mammalian host, or non-culture purification route), or where “purified from mammalian cells grown in culture” is not satisfied.
- A defendant can argue either:
- the EPO was not purified from mammalian cells grown in culture, or
- the accused process does not meet the claimed purification-source condition, even if the final EPO is structurally human.
Claim 2 (preparation / formulation)
Claim 2 recites:
- “a pharmaceutically-acceptable preparation containing a therapeutically effective amount of erythropoietin”
- where “human serum albumin is mixed with said erythropoietin.”
Scope implications
- Claim 2 is narrower than Claim 1 because it requires HSA as an ingredient.
- It does not specify:
- the weight percent or concentration range of HSA,
- whether HSA is recombinant or plasma-derived,
- whether HSA is the only stabilizer/excipient,
- buffer composition, pH, ionic strength, or container closure details.
Critical pressure points
- Claim 2 covers a formulation concept that can be widely used in biologics as a stabilizer.
- Breadth risk for the patentee: Claim 2 may be vulnerable to prior art that discloses HSA-containing EPO preparations, even if the prior art differs in HSA concentration, manufacturing details, or packaging format.
- Infringement risk for competitors: if they use HSA with EPO in any “pharmaceutically acceptable preparation” setting, they are inside the literal claim language even if the rest of the formulation differs.
How do these claims position against the known EPO patent and product timeline in the US?
EPO commercialization in the US occurred around early-to-mid 1989 with recombinant human EPO products developed from mammalian cell expression systems and formulated with stabilizers. By the early 1990s, the dominant industrial EPO route used mammalian expression and purification to obtain biologically active EPO, then stabilized for storage and administration.
Where 5,955,422 fits conceptually
- Claim 1 attempts to tie composition novelty to a mammalian-culture derived purification source, rather than to EPO sequence or therapeutic method claims.
- Claim 2 targets a specific formulation excipient: human serum albumin mixed with EPO.
Landscape consequence
- The claim set looks like an effort to lock in protection for:
1) a production-route-defined product category (Claim 1), and
2) a formulation stabilized by HSA (Claim 2).
- That is the typical posture for follow-on protection as the base biologic enters the market: protect incremental process/source and formulation.
Critical lens
- For Claim 1, the main landscape question becomes whether prior US filings already disclosed EPO purified from mammalian cell culture, even if phrased differently (for example, “recombinant EPO produced in mammalian cells” coupled with pharmaceutical compositions).
- For Claim 2, the main landscape question becomes whether prior US filings disclosed EPO formulations with HSA, even if the earlier claim used slightly different language (such as “albumin” without specifying “human serum albumin,” or using other stabilizers that included HSA).
Because the only claims provided are 1 and 2, the analysis below focuses on these two claim pillars.
What prior art categories likely matter most?
1) EPO itself: recombinant EPO from mammalian cell culture
If US prior art discloses recombinant human EPO produced in mammalian cells, purified from those cultures, and formulated for therapeutic use, it can attack Claim 1 as anticipated or obvious.
Why it is relevant
- Claim 1 does not restrict:
- cell line type,
- expression system (transient vs stable),
- purification strategy (chromatography vs membrane steps),
- impurity profile,
- final formulation details beyond “pharmaceutically acceptable diluent, adjuvant or carrier.”
If earlier patents disclose EPO produced and purified from mammalian cultures and administered as a pharmaceutical composition, Claim 1’s additional language may be redundant.
2) Formulation know-how: albumin-stabilized biologics and EPO
Albumin has long been used as a stabilizer for protein therapeutics to protect against adsorption and aggregation.
Why it is relevant
- Claim 2 is limited to HSA mixed with EPO.
- If earlier US filings describe EPO formulations containing human serum albumin, Claim 2 can be anticipated.
Even if earlier art includes albumin without explicitly naming “human serum albumin,” those differences can become material for strict anticipation, but they still matter for obviousness if albumin identity was routine.
3) Product-by-process exposure for Claim 1
Product-by-process claims can survive anticipation only where the prior art does not disclose the same process or where the resulting product is distinguishable.
Why it is relevant
- Claim 1’s novelty hinges on purification from mammalian cell culture.
- If prior art EPO is produced similarly, distinguishing the accused product requires proof that the purification-source condition is not met.
Does Claim 1 plausibly read on mainstream recombinant EPO manufacturing?
Yes, on its face.
Claim 1’s requirement
- “purified from mammalian cells grown in culture” matches mainstream recombinant EPO production practice.
Critical question for competitors
- If an accused EPO drug product uses mammalian cell culture expression and purification, the condition is likely met.
- If a competitor uses a different host system or produces EPO via non-mammalian steps where purification does not begin from “mammalian cells grown in culture,” they can potentially avoid Claim 1.
Scope control
- The claim’s lack of additional structural or functional limitations makes it hard for the patentee to defend narrow scope.
Does Claim 2 cover common EPO stability formulations?
Yes.
Claim 2’s requirement
- “human serum albumin is mixed with said erythropoietin.”
This is a formulation-level limitation that is easy to satisfy in practice if HSA is used as a stabilizer.
Critical questions for the landscape
- How frequently does HSA appear in EPO products?
- Do earlier filings claim or disclose HSA-containing EPO formulations?
If earlier US patents already disclose the combination, Claim 2 is likely crowded.
Where is the infringement boundary likely to sit?
Claim 1 boundary (process/source)
Likely outside if the accused EPO is not purified from mammalian cell culture.
Likely inside if:
- EPO is produced in mammalian cells (even widely used lines) and purified from those cultures, and
- the final product is administered as a pharmaceutical composition with acceptable carriers/diluents.
Claim 2 boundary (excipient)
Likely inside if:
- HSA is used and mixed with EPO in a “pharmaceutically-acceptable preparation,” regardless of other excipients.
Likely outside if:
- HSA is not used, or
- the formulation uses a different albumin source (for example, no “human serum albumin”) or avoids albumin entirely.
How does this patent fit into the typical US biologics follow-on landscape?
US patent strategy around EPO often splits protection across:
- upstream manufacturing/process,
- product (sequence/biological activity),
- formulation/stabilization,
- device and administration formats,
- and later generics/biosimilar “skinny label” and formulation differences.
Given Claim 1 and Claim 2 are formulation and product-by-process style, US 5,955,422 is positioned as a secondary protection patent. It likely targets incremental value in protecting commercially used EPO compositions rather than re-litigating the core recombinant EPO invention.
Critical implication
- Secondary patents with broad formulation language can face heavy prior art pressure and easy design-around only if excipients are changed.
What is the most actionable landscape impact for R&D and investment?
For R&D teams developing competing EPOs or biosimilars
- Excipient strategy is a design-around lever. Claim 2 is excipient-specific (HSA). Substituting stabilizers or changing albumin identity can avoid Claim 2 if it is not replaced with HSA.
- Manufacturing documentation matters for Claim 1. Claim 1’s product-by-process limitation can be impacted by upstream host systems and purification origin.
For investment screening
- A patent with:
- broad “therapeutically effective amount” language,
- wide carrier allowance,
- and two key limiting features tied to
- mammalian-culture purification source, and
- HSA formulation,
is likely to be high-friction in validity contests if those features are widely disclosed in earlier patents or widely used in marketed products.
What does a critical claims construction suggest about enforceability?
Claim 1 enforceability signals
- It is broad across formulations and carriers.
- It depends on the accused EPO meeting the purification source condition.
- It can become difficult to enforce in litigation if the accused product is produced by mammalian-culture methods and the prior art already discloses those methods.
Claim 2 enforceability signals
- It is narrower because it requires HSA.
- It is likely crowded by earlier EPO formulation disclosures and common protein stabilization practices.
- If prior art already teaches HSA-containing EPO preparations, the claim’s novelty is constrained to differences in concentration ranges, manufacturing details, or specific preparation formats not present in the provided claim language.
Key Takeaways
- US 5,955,422 claim 1 covers pharmaceutical compositions of human EPO where the EPO is “purified from mammalian cells grown in culture,” leaving broad room on formulation carriers and diluents and turning enforceability into a product-by-process question.
- US 5,955,422 claim 2 covers EPO preparations specifically mixed with human serum albumin, making excipient selection a primary design-around route.
- The claim language tracks widely used industry practices (mammalian cell-based recombinant EPO and albumin-stabilized protein therapeutics), which increases prior art and validity pressure in the US patent landscape.
FAQs
1) What is the single most important limitation in Claim 1?
“Purified from mammalian cells grown in culture.”
2) What is the single most important limitation in Claim 2?
Human serum albumin mixed with erythropoietin.
3) Can Claim 1 be avoided without changing the active ingredient?
Yes, by changing the upstream host/purification origin so it is not “purified from mammalian cells grown in culture,” or by demonstrating that the accused product does not meet that process-source limitation.
4) Can Claim 2 be avoided by changing stabilizers?
Yes. Avoiding human serum albumin in the formulation is the direct design-around lever.
5) Is the claim scope more about formulation or manufacturing?
Both, with Claim 2 being formulation-centric (HSA) and Claim 1 being manufacturing/process-source centric (mammalian culture purification).
References
[1] USPTO. United States Patent 5,955,422. (Patent document).
More… ↓
⤷ Start Trial
|
